Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)Food_i SenseNCT07626658
Food-i-Sense Analytics: Integrating AI Into Continuous Glucose Monitoring Data Analysis for Precision Nutrition.
An observational study of Prediabetes (Insulin Resistance, Impaired Glucose Tolerance) and Artificial Intelligence Mobile Application, run by IMDEA Food at 1 site in Spain.
Trial summary
This study aims to improve how we understand and manage blood sugar responses in adults without diabetes. Even in people who appear healthy, blood sugar levels after meals can behave in different ways. These patterns may help predict future risk of diseases such as type 2 diabetes or other cardiometabolic problems. Read more about this study
- Who is it for?
- Ages 18 to 70 yearsHealthy volunteers can take part
- Conditions the study is for
- Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), Artificial Intelligence Mobile Application
- What is being tested?
- Continuous glucose monitoring using a wearable sensor (flash interstitial glucose monitor)
- Type of treatment
- Medical device
- How many people
- 471 participants
- Where
- 1 siteSpain
- Study dates
- 15 Oct 2026to Dec 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: The study population consists of community-dwelling adults aged 18-70 years, recruited from the general population through public advertisements, university campus postings, pharmacies, and primary care centers. Participants represent a broad, non-clinical community sample without diagnosed diabetes or severe metabolic disease. Recruitment is open to individuals living independently and able to maintain their usual daily routines. The population reflects a heterogeneous mix of sociodemographic backgrounds to ensure variability in dietary habits, lifestyle patterns, and glucose-response profiles.
Who may be able to join
- Adults aged 18 to 70 years.
- Willing and able to undergo 14 days of continuous glucose monitoring (CGM) using a wearable sensor.
- Able to maintain stable dietary habits during the monitoring period.
- Able and willing to complete dietary records, including two structured 3-day food logs.
- Able and willing to photograph all meals during the 14-day monitoring period following instructions provided.
- Able to keep a record of physical activity as instructed.
Show all 9Show fewer
- No previous diagnosis of diabetes or other serious metabolic disorders.
- Sufficient commitment and availability to attend all study visits (screening, baseline evaluation, final evaluation).
- Capable of providing written informed consent.
Who cannot join
- Diagnosed diabetes mellitus or other serious metabolic disorders.
- History of severe gastrointestinal, cardiovascular, or other medical conditions that may interfere with stable diet or physical activity during the study.
- Pregnant or breastfeeding women.
- Inability or unwillingness to comply with continuous glucose monitoring (CGM) procedures for 14 days.
- Participants with skin conditions or allergies that prevent safe use of a CGM sensor.
- Current participation in another clinical trial that could affect study results.
Show all 9Show fewer
- Use of medications that significantly alter glucose metabolism or interfere with CGM accuracy.
- Inability to attend all scheduled study visits or complete required records (diet logs, photos, questionnaires).
- Any condition judged by the investigators to make the participant unsuitable for the study or unable to provide informed consent.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Spain1 site, 1 recruiting
- Recruiting
IMDEA Nutrition
Madrid, Madrid, 28049
Lidia Daimiel, PhD, +34 655250563, lidia.daimiel@nutricion.imdea.org
Lorena López, lorena.lopez@nutricion.imdea.org
About this study
Official title: Food_i Sense Analytics: Integrando la Inteligencia Artificial Con la monitorización Continua de la Glucosa Para la nutrición de precisión
This study aims to improve how we understand and manage blood sugar responses in adults without diabetes. Even in people who appear healthy, blood sugar levels after meals can behave in different ways. These patterns may help predict future risk of diseases such as type 2 diabetes or other cardiometabolic problems.
To study this, researchers at IMDEA Nutrition have developed a computer algorithm called GLIA, which uses artificial intelligence (AI) to analyze continuous glucose monitoring (CGM) data. The goal is to classify people into different "glucotypes", meaning typical patterns of how their blood sugar behaves throughout the day. These glucotypes could help tailor dietary recommendations in the future.
Read more
Goals of the study
- Train and validate the GLIA algorithm** in a large and diverse sample of adults.
- Study how glucotypes relate to health indicators**, such as blood pressure, body composition, cholesterol, or lifestyle.
- Predict how each person responds to different foods**, to support personalized nutrition advice.
Who can participate?
Adults 18-70 years old who:
- Do not*have diagnosed diabetes or serious metabolic disease.
- Agree to wear a glucose sensor for 14 days.
- Can keep stable eating habits and record diet and physical activity.
What participation involves
The study lasts 3 weeks and includes 3 visits:
Visit 1 - Screening (20 min):
- Review of eligibility criteria.
- Explanation of the study.
- Signing informed consent.
- Visit 2 - Initial assessment (45 min)
- Collection of personal and health information.
- Measurements: weight, height, waist, body composition, blood pressure.
- Placement of a FreeStyle Libre 3 CGM sensor.
- Instructions for:
- Completing two 3-day food records (one each week).
- Taking photos of all meals.
- Reporting physical activity.
Continuous monitoring (14 days)
Visit 3 - Final evaluation (45 min)
- Review of diet records.
- Repeat measurements.
- Blood and urine samples are collected for metabolic and molecular analyses.
Meal photos are analyzed using an AI-based food recognition model. The system identifies foods and estimates nutrients (macronutrients, vitamins, minerals, glycemic index, etc.). This helps researchers understand how meals relate to blood sugar patterns.
Potential benefits: Although participants may not receive direct health benefits, the study will:
- Improve understanding of how healthy people process glucose.
- Help identify early risk markers for metabolic diseases.
- Contribute to developing personalized nutrition tools based on individual glucose responses.
Risks: are minimal and mainly include:
- Mild skin irritation from the CGM sensor.
- Temporary discomfort from blood draw.
Read the detailed description
The Food_iSense Analytics (FiS) study is an observational, cross-sectional protocol designed to advance precision nutrition through the integration of continuous glucose monitoring (CGM), artificial intelligence (AI), and comprehensive phenotyping. The project builds upon preliminary work using data from the ENSATI and TEMPUS studies, where the research team developed GLIA, an AI-driven algorithm capable of generating individualized glucotypes-patterns of glycemic behavior that reflect the dynamic response of glucose to daily living conditions and meal intake.
Scientific Background and Rationale Although individuals without diagnosed diabetes may exhibit blood glucose values within standard reference intervals, the shape, duration, and variability of glucose excursions reflect underlying physiological regulation and may reveal early signs of metabolic dysfunction. Research has demonstrated high inter-individual variability in glycemic responses to identical meals, suggesting that dietary guidelines must move toward personalization.
The introduction of CGM devices (FreeStyle Libre 3) allows for high-resolution temporal data capturing minute-to-minute changes in interstitial glucose. However, traditional CGM metrics (mean glucose, time in range, coefficient of variation) do not sufficiently capture the full complexity of glucose dynamics.
GLIA addresses this limitation by extracting multidimensional features that quantify:
Peak morphology: slope, amplitude, recovery time, decay kinetics. Variability features: short- and long-term variability indexes, glycemic volatility, post-prandial oscillation density.
Chrononutrition-related features: differences in glycemic control across circadian windows (morning/afternoon/evening), alignment with habitual eating patterns.
Derived metrics: composite indexes generated via principal component analysis (PCA) and clustering.
Using machine learning and unsupervised clustering with bootstrapping, GLIA identifies stable glucose response phenotypes. These glucotypes are then examined in relation to health indicators, dietary patterns, and predictive models of individual glycemic responses.
Study Structure and Workflow Overview
The study consists of three in-person visits across approximately 21 days, during which participants undergo:
Initial assessment (demographics, anthropometrics, medical history, baseline health measures).
Continuous 14-day CGM period with detailed dietary monitoring using:
Two structured 3-day dietary records Automated AI-based food image recognition Mediterranean diet and ultraprocessed food questionnaires Physical activity questionnaires
Final assessment including biological sample collection (fasting blood and first-morning urine), updated anthropometry, and final quality check of all dietary records.
The final dataset incorporates more than 140 nutritional variables per food item, combined with high-resolution glucose time-series data, clinical phenotype, and multiple molecular biomarkers.
Registry-Related Quality Procedures and Data Governance Although this study is not a patient registry in the classical sense, the research team implements registry-grade data management procedures due to the scale, multidimensionality, and long-term value of the dataset. The following subsections reflect the registry-quality framework.
- Quality Assurance Plan A comprehensive quality assurance (QA) plan governs all activities from recruitment to data analysis. Key components include: Standardized training of all personnel (dietitians, research nurses, data managers). Calibration schedules for anthropometric devices (stadiometer, scale, bioimpedance instruments) and for blood pressure monitors. Daily consistency checks of CGM data uploads. Protocol deviation logs documenting missing measurements, device issues, and participant non-compliance. Internal monthly audits performed by the IMDEA Quality Office to verify protocol adherence. Independent external audit capability is maintained, though audits are not routinely scheduled unless required by funders or ethics committees.
- Data Validation and Automated Data Checks Incoming data are processed through a multi-stage validation pipeline:
- Range and plausibility checks Automatic filtering flags values outside expected biological ranges (e.g., impossible BMI, extreme macronutrient percentages, duplicate CGM timestamps).
- Internal consistency checks Cross-field validation identifies inconsistencies, such as: caloric intake mismatching macronutrient totals, dietary patterns incompatible with photographed meals, anthropometric values inconsistent across visits.
- Technical consistency CGM streams are checked for: signal dropouts longer than 15 minutes, abrupt shifts indicating sensor displacement, unrealistic glucose kinetics (rise/decay rates). Problematic sections are annotated but not deleted, preserving data integrity for sensitivity analyses.
- Source Data Verification (SDV) To ensure data accuracy and representativeness: Dietary records are cross-validated against food photographs and questionnaire responses. Medical history and medication data are verified against documents participants bring to Visit 2 (e.g., lab reports ≤ 6 months old). Blood pressure and anthropometry undergo dual measurement with two assessors performing random checks on 10% of sessions. CGM data are compared with participant logs describing sensor issues, physical activity peaks, and atypical meals. All verification steps follow Good Clinical Practice (GCP) documentation practices.
- Data Dictionary and Variable Coding
The study uses an extensive data dictionary organized into modules:
Sociodemographic module
Definitions, coding schemes (e.g., ISCED for education), universe and skip patterns.
Clinical phenotype module
Standard coding for medical conditions using ICD-10 when applicable. Definitions of metabolic syndrome markers and derived variables.
Anthropometry and body composition
Measurement rules, rounding conventions, and device-specific calibrations.
CGM module
Time-series format, sampling interval, sensor metadata, derived features, preprocessing rules.
Dietary variables
Food items mapped to validated food composition databases for Spain. Nutrient coding includes standardized units and upper/lower expected ranges.
Molecular biomarkers
Units, assay platforms, storage conditions, and laboratory reference values.
The dictionary includes more than 500 entries and is version-controlled.
SOPs govern all operational and analytic tasks, including:
Recruitment and informed consent CGM application, monitoring, and removal Anthropometric and BIA measurement Blood/urine sample collection, processing, aliquoting, and storage Data entry and double-entry verification for paper forms Food image capture guidelines and data upload protocol Use of the AI food-recognition system and manual override procedures Documentation of adverse events related to CGM or blood collection Dataset freeze procedures and change control for analysis scripts Secure storage, encryption, and pseudonymization workflows
SOPs are reviewed periodically and updated as needed.
- Sample Size Assessment
Using synthetic data generated during algorithm development, investigators determined that approximately 392 complete datasets provide adequate clustering stability:
Maximization of the Silhouette score (~0.67 at n=392). Near-minimal Davies-Bouldin index at ~392-588 samples. Robust PCA component stability at ≥350 participants.
Accounting for a 20% potential data-loss rate, 471 participants are targeted for recruitment.
- Missing Data Plan Missingness may arise from incomplete dietary records, sensor failures, lost images, or participant withdrawal.
The plan includes:
Classification of missingness as MCAR, MAR, or MNAR. Short-gap interpolation for CGM data gaps ≤ 20 minutes using cubic spline or Kalman smoothing.
Exclusion of unusable segments (e.g., sensor warm-up periods). Multiple imputation (MI) for covariates such as weight or blood pressure if only one visit yields valid measures.
Complete-case sensitivity analyses to confirm robustness of imputed models.
Retention strategies minimize missing data, but high technical data density ensures analytic viability even with partial loss.
- Statistical Analysis Plan (SAP) The SAP covers both algorithm validation and hypothesis-generating analyses. 8.1 Preprocessing
CGM normalization to individual baselines. PCA for dimensionality reduction. Unsupervised clustering (k-means and hierarchical) with bootstrapping. Feature engineering for peak characteristics and chrononutrition variables.
8.2 Glucotype generation and validation
Internal validation with Silhouette, Calinski-Harabasz, and Davies-Bouldin metrics.
Stability assessment through subsampling and perturbation tests.
8.3 Association analyses
ANOVA/Kruskal-Wallis for between-glucotype comparisons. Logistic and linear regression adjusting for key confounders. MANOVA for overall cardiometabolic profiles.
8.4 Dietary modelling
Multiple Correspondence Analysis (MCA) for dietary pattern extraction. Regression models linking nutrient intake to glucotype. Machine learning models (Random Forest, SVM, XGBoost) to predict meal-level glucose responses.
8.5 Predictive simulations Agent-based modelling is used to simulate hypothetical diet changes and predict personalized glucose responses under various nutritional scenarios.
8.6 Software and reproducibility Analyses are performed in Python and R, with scripts managed through version control, containerization (Docker), and reproducibility logs.
Conclusion The FiS protocol integrates advanced CGM analytics, AI-driven phenotyping, and detailed dietary and biochemical profiling to map the diversity of glucose regulation in adults without diabetes. The study applies rigorous registry-level quality procedures, including automated data validation, structured data dictionaries, SOPs, and a comprehensive statistical analysis plan. The resulting dataset and validated algorithm will support future work in personalized nutrition, early risk detection, and tailored dietary interventions.
- Conditions
- Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), Artificial Intelligence Mobile Application
- Being tested
- Continuous glucose monitoring using a wearable sensor (flash interstitial glucose monitor)
- Keywords
- Continuous glucose monitoring (CGM), Glucose dynamics, Glucose phenotyping, Glucotypes, Artificial intelligence, Nutrition, Machine-learning, Glucose patterns, Precision nutrition, Chrononutrition, Glycemic variability, Nutritional pattern, Glycemic response modeling, Personalized dietary recommendations, Multimodal metabolic phenotyping, Wearable glucose sensors, AI-driven health monitoring, Cardiometabolic health, Adults Without Diabetes
- Medical subject headings
- Prediabetic State, Insulin Resistance, Glucose Intolerance
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Continuous glucose monitoring using a wearable sensor (flash interstitial glucose monitor)Device
The intervention consists of applying and wearing a 14-day continuous glucose monitoring (CGM) device that captures interstitial glucose every minute under free-living conditions. This wearable flash sensor is used exclusively for passive data collection; it does not provide insulin delivery, therapeutic adjustments, or real-time clinical management. What distinguishes this intervention is its integration into a multimodal data-capture system: participants simultaneously complete structured dietary records, submit standardized meal photographs for AI-based food recognition, and undergo detailed phenotyping. The CGM data are then processed through the study's proprietary GLIA algorithm to derive individualized glucose-response patterns ("glucotypes"). This combination of high-frequency glucose monitoring, dietary image analytics, and machine-learning modeling differentiates the device's use from typical clinical or self-management applications in other studies.
| Study group | Role | What they receive |
|---|---|---|
| Food_iSense Analytics Cohort | This cohort includes adults aged 18-70 years without diagnosed diabetes who undergo continuous glucose monitoring (CGM) for 14 days using a FreeStyle Libre 3 sensor. Participants complete structured dietary records, provide meal photographs for AI-based food recognition, and answer validated nutrition and physical-activity questionnaires. Anthropometry, body composition, blood pressure, and recent clinical history are collected at study visits. At the end of monitoring, fasting blood and first-morning urine samples are obtained for biochemical and molecular analyses. No therapeutic intervention is administered; instead, the study characterizes natural glucose-response patterns ("glucotypes") under free-living conditions and evaluates how diet, lifestyle, and metabolic traits relate to glycemic dynamics to support future precision-nutrition strategies. Receives: Device: Continuous glucose monitoring using a wearable sensor (flash interstitial glucose monitor) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Glucotype Classification Derived From Continuous Glucose Monitoring Data
The primary outcome is the glucotype assigned to each participant based on analysis of the 14-day continuous glucose monitoring (CGM) trace. Glucotypes reflect individualized patterns of glucose dynamics, capturing peak shape, amplitude, recovery, variability, and chrononutrition-related fluctuations. The classification is generated using the GLIA machine-learning algorithm, which incorporates preprocessing (normalization, artifact detection), multivariate feature extraction (including peak morphology descriptors, temporal patterns, and variability metrics), and unsupervised clustering with stability assessment. The outcome quantifies each participant's predominant glucose-response phenotype under free-living conditions and serves as the foundation for assessing associations with dietary intake, metabolic traits, and predictive modeling of glycemic responses.
Measured: Assessed continuously over 14 days of CGM wear, with glucotype classification calculated after completion of the full 14-day glucose-monitoring period for each participant.
Secondary outcomes (13)
Body mass index
BMI is calculated as weight (kg) divided by height (m²). It provides an estimate of overall body size and is used to characterize participants' cardiometabolic phenotype. Measurements are taken using calibrated scales and stadiometers according to standardized anthropometric procedures.
Measured: Measured during Visit 2 and Visit 3 across the 14-day monitoring period.
Waist circunference
Waist circumference (cm) is measured at the midpoint between the last rib and the iliac crest using a flexible tape. It reflects central adiposity and is used to evaluate abdominal fat distribution, a key cardiometabolic risk marker. Two measurements are averaged.
Measured: Assessed during Visit 2 and Visit 3 within the 14-day monitoring period.
Body Fat Percentage
Body fat percentage is obtained using bioelectrical impedance analysis (BIA). It quantifies total adiposity and contributes to understanding metabolic status and its association with glucotype patterns.
Measured: Measured during Visit 2 and Visit 3 across the 14-day monitoring period.
Muscle mass
Muscle mass (kg and %) is determined using segmental BIA. This measure helps characterize body composition and assess relationships between lean mass and glucose-response patterns.
Measured: Measured during Visit 2 and Visit 3 within the 14-day CGM period.
Visceral Fat Index
The visceral fat index is derived from BIA and represents estimated deep abdominal fat levels. Elevated visceral fat is associated with insulin resistance and cardiometabolic risk, making it relevant to glucotype interpretation.
Measured: Measured during Visit 2 and Visit 3 over the 14-day monitoring period.
Resting Metabolic Rate (RMR)
RMR is estimated via BIA and expressed in kilocalories per day. It reflects basal energy expenditure and may relate to individualized glucose variability and metabolic patterns.
Measured: Measured during Visit 2 and Visit 3 during the 14-day CGM period.
Blood Pressure (Systolic and Diastolic)
Blood pressure is measured in mmHg using a validated automatic device (three readings averaged). It provides an indicator of cardiovascular status to explore associations with glucose-response phenotypes.
Measured: Measured during Visit 2 and Visit 3 within the 14-day monitoring period.
Fasting Glucose
Fasting plasma glucose (mg/dL) is obtained from venous blood after an overnight fast. It reflects baseline glycemic control and is used to characterize metabolic status in relation to glucotypes.
Measured: Collected once during Visit 3 after completion of the 14-day monitoring period.
Hemoglobin A1c (HbA1c)
HbA1c (%) measures average glucose control over the prior 2-3 months. Although participants are non-diabetic, HbA1c helps assess subtle alterations in glycemic regulation associated with glucotypes.
Measured: Measured during Visit 3 following the 14-day CGM period.
Total Cholesterol
Total cholesterol (mg/dL) is quantified from fasting blood samples to evaluate lipid status. Its relationship with glucotype-derived metabolic phenotypes will be explored.
Measured: Assessed during Visit 3 after completion of the 14-day monitoring period.
LDL Cholesterol
LDL (mg/dL) is calculated with the Friedewald formula
Measured: Measured during Visit 3 following the 14-day CGM period.
HDL Cholesterol
HDL cholesterol is assessed from fasting blood samples and reflects protective lipid status. Associations with glucose-response patterns will be evaluated.
Measured: Measured during Visit 3 after the 14-day monitoring period.
Triglycerides
Fasting triglycerides (mg/dL) are measured from venous blood obtained during the end-of-study visit. Triglyceride concentration reflects circulating lipid metabolism and is an important cardiometabolic risk indicator. This outcome assesses whether triglyceride levels differ across glucotypes or relate to glucose-response features such as postprandial peak amplitude or glycemic variability. Analyses will explore associations using regression models adjusted for demographic and clinical covariates.
Measured: Assessed during Visit 3 after completion of the 14-day monitoring period.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Jun 2026
- Study start15 Oct 2026
- Primary completionMay 2028 (estimated)
- Study completionDec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (8)Papers the sponsor has linked to this study.
- Other trials for Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 471 participants (estimated)
Sponsor and investigators
- Lead sponsor
- IMDEA Food
- Sponsor type
- University, hospital or other
- Collaborators
- Abbott Laboratories (Pak) Ltd.
- Responsible party
- Principal investigator, Lidia Daimiel Ruiz, IMDEA Food
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07626658
- Sponsor's protocol ID
- IMD PI-078
- Acronym
- Food_i Sense
- Status last verified
- Nov 2026
- First submitted
- 27 May 2026
- Last updated
- 5 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- Yes: De-identified individual participant data will be made available to qualified researchers upon reasonable request. All shared datasets will undergo double codification, meaning two independent pseudonymization layers are applied before external release: one ID replacing personal identifiers within IMDEA Nutrition, and a second external-use ID generated solely for data sharing. No key linking either code to participant identities will be shared. Data will be accessible only for ethically approved scientific purposes and after signing a data-sharing agreement outlining permitted use, data-security requirements, and obligations to prevent re-identification. Access will be provided through secure, controlled-transfer procedures.
Publications
Klonoff DC, Nguyen KT, Xu NY, Gutierrez A, Espinoza JC, Vidmar AP. Use of Continuous Glucose Monitors by People Without Diabetes: An Idea Whose Time Has Come? J Diabetes Sci Technol. 2023 Nov;17(6):1686-1697. doi: 10.1177/19322968221110830. Epub 2022 Jul 20.
PubMed 35856435Hengist A, Ong JA, McNeel K, Guo J, Hall KD. Imprecision nutrition? Intraindividual variability of glucose responses to duplicate presented meals in adults without diabetes. Am J Clin Nutr. 2025 Jan;121(1):74-82. doi: 10.1016/j.ajcnut.2024.10.007. Epub 2024 Dec 2.
PubMed 39755436Mao Y, Tan KXQ, Seng A, Wong P, Toh SA, Cook AR. Stratification of Patients with Diabetes Using Continuous Glucose Monitoring Profiles and Machine Learning. Health Data Sci. 2022 Apr 27;2022:9892340. doi: 10.34133/2022/9892340. eCollection 2022.
PubMed 38487483Hall H, Perelman D, Breschi A, Limcaoco P, Kellogg R, McLaughlin T, Snyder M. Glucotypes reveal new patterns of glucose dysregulation. PLoS Biol. 2018 Jul 24;16(7):e2005143. doi: 10.1371/journal.pbio.2005143. eCollection 2018 Jul.
PubMed 30040822Zeevi D, Korem T, Zmora N, Israeli D, Rothschild D, Weinberger A, Ben-Yacov O, Lador D, Avnit-Sagi T, Lotan-Pompan M, Suez J, Mahdi JA, Matot E, Malka G, Kosower N, Rein M, Zilberman-Schapira G, Dohnalova L, Pevsner-Fischer M, Bikovsky R, Halpern Z, Elinav E, Segal E. Personalized Nutrition by Prediction of Glycemic Responses. Cell. 2015 Nov 19;163(5):1079-1094. doi: 10.1016/j.cell.2015.11.001.
PubMed 26590418van Doorn WPTM, Foreman YD, Schaper NC, Savelberg HHCM, Koster A, van der Kallen CJH, Wesselius A, Schram MT, Henry RMA, Dagnelie PC, de Galan BE, Bekers O, Stehouwer CDA, Meex SJR, Brouwers MCGJ. Machine learning-based glucose prediction with use of continuous glucose and physical activity monitoring data: The Maastricht Study. PLoS One. 2021 Jun 24;16(6):e0253125. doi: 10.1371/journal.pone.0253125. eCollection 2021.
PubMed 34166426Barrea L, Verde L, Colao A, Mandarino LJ, Muscogiuri G. Medical nutrition therapy for the management of type 2 diabetes mellitus. Nat Rev Endocrinol. 2025 Dec;21(12):769-782. doi: 10.1038/s41574-025-01161-5. Epub 2025 Aug 15.
PubMed 40817355Safiri S, Karamzad N, Kaufman JS, Bell AW, Nejadghaderi SA, Sullman MJM, Moradi-Lakeh M, Collins G, Kolahi AA. Prevalence, Deaths and Disability-Adjusted-Life-Years (DALYs) Due to Type 2 Diabetes and Its Attributable Risk Factors in 204 Countries and Territories, 1990-2019: Results From the Global Burden of Disease Study 2019. Front Endocrinol (Lausanne). 2022 Feb 25;13:838027. doi: 10.3389/fendo.2022.838027. eCollection 2022.
PubMed 35282442
Study at a glance
From the registry record, last updated by the sponsor on 5 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Food_i Sense Analytics: Integrando la Inteligencia Artificial Con la monitorización Continua de la Glucosa Para la nutrición de precisión
- ClinicalTrials.gov ID
- NCT07626658
- Acronym / sponsor ID
- Food_i Sense / IMD PI-078
- Conditions
- Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), Artificial Intelligence Mobile Application
- Keywords
- Continuous glucose monitoring (CGM), Glucose dynamics, Glucose phenotyping, Glucotypes, Artificial intelligence, Nutrition, Machine-learning, Glucose patterns
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 471 participants (estimated)
- Lead sponsor
- IMDEA FoodUniversity, hospital or other
- Collaborators
- Abbott Laboratories (Pak) Ltd.
- Study start
- 15 Oct 2026 (actual)
- Primary completion
- May 2028 (estimated)
- Study completion
- Dec 2028 (estimated)
- First posted
- 4 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to improve how we understand and manage blood sugar responses in adults without diabetes. Even in people who appear healthy, blood sugar levels after meals can behave in different ways. These patterns may help predict future risk of diseases such as type 2 diabetes or other cardiometabolic problems.
To study this, researchers at IMDEA Nutrition have developed a computer algorithm called GLIA, which uses artificial intelligence (AI) to analyze continuous glucose monitoring (CGM) data. The goal is to classify people into different "glucotypes", meaning typical patterns of how their blood sugar behaves throughout the day. These glucotypes could help tailor dietary recommendations in the future.
Goals of the study
- Train and validate the GLIA algorithm** in a large and diverse sample of adults.
- Study how glucotypes relate to health indicators**, such as blood pressure, body composition, cholesterol, or lifestyle.
- Predict how each person responds to different foods**, to support personalized nutrition advice.
Who can participate?
Adults 18-70 years old who:
- Do not*have diagnosed diabetes or serious metabolic disease.
- Agree to wear a glucose sensor for 14 days.
- Can keep stable eating habits and record diet and physical activity.
What participation involves
The study lasts 3 weeks and includes 3 visits:
Visit 1 - Screening (20 min):
- Review of eligibility criteria.
- Explanation of the study.
- Signing informed consent.
- Visit 2 - Initial assessment (45 min)
- Collection of personal and health information.
- Measurements: weight, height, waist, body composition, blood pressure.
- Placement of a FreeStyle Libre 3 CGM sensor.
- Instructions for:
- Completing two 3-day food records (one each week).
- Taking photos of all meals.
- Reporting physical activity.
Continuous monitoring (14 days)
Visit 3 - Final evaluation (45 min)
- Review of diet records.
- Repeat measurements.
- Blood and urine samples are collected for metabolic and molecular analyses.
Meal photos are analyzed using an AI-based food recognition model. The system identifies foods and estimates nutrients (macronutrients, vitamins, minerals, glycemic index, etc.). This helps researchers understand how meals relate to blood sugar patterns.
Potential benefits: Although participants may not receive direct health benefits, the study will:
- Improve understanding of how healthy people process glucose.
- Help identify early risk markers for metabolic diseases.
- Contribute to developing personalized nutrition tools based on individual glucose responses.
Risks: are minimal and mainly include:
- Mild skin irritation from the CGM sensor.
- Temporary discomfort from blood draw.
Detailed description
The Food_iSense Analytics (FiS) study is an observational, cross-sectional protocol designed to advance precision nutrition through the integration of continuous glucose monitoring (CGM), artificial intelligence (AI), and comprehensive phenotyping. The project builds upon preliminary work using data from the ENSATI and TEMPUS studies, where the research team developed GLIA, an AI-driven algorithm capable of generating individualized glucotypes-patterns of glycemic behavior that reflect the dynamic response of glucose to daily living conditions and meal intake.
Scientific Background and Rationale Although individuals without diagnosed diabetes may exhibit blood glucose values within standard reference intervals, the shape, duration, and variability of glucose excursions reflect underlying physiological regulation and may reveal early signs of metabolic dysfunction. Research has demonstrated high inter-individual variability in glycemic responses to identical meals, suggesting that dietary guidelines must move toward personalization.
The introduction of CGM devices (FreeStyle Libre 3) allows for high-resolution temporal data capturing minute-to-minute changes in interstitial glucose. However, traditional CGM metrics (mean glucose, time in range, coefficient of variation) do not sufficiently capture the full complexity of glucose dynamics.
GLIA addresses this limitation by extracting multidimensional features that quantify:
Peak morphology: slope, amplitude, recovery time, decay kinetics. Variability features: short- and long-term variability indexes, glycemic volatility, post-prandial oscillation density.
Chrononutrition-related features: differences in glycemic control across circadian windows (morning/afternoon/evening), alignment with habitual eating patterns.
Derived metrics: composite indexes generated via principal component analysis (PCA) and clustering.
Using machine learning and unsupervised clustering with bootstrapping, GLIA identifies stable glucose response phenotypes. These glucotypes are then examined in relation to health indicators, dietary patterns, and predictive models of individual glycemic responses.
Study Structure and Workflow Overview
The study consists of three in-person visits across approximately 21 days, during which participants undergo:
Initial assessment (demographics, anthropometrics, medical history, baseline health measures).
Continuous 14-day CGM period with detailed dietary monitoring using:
Two structured 3-day dietary records Automated AI-based food image recognition Mediterranean diet and ultraprocessed food questionnaires Physical activity questionnaires
Final assessment including biological sample collection (fasting blood and first-morning urine), updated anthropometry, and final quality check of all dietary records.
The final dataset incorporates more than 140 nutritional variables per food item, combined with high-resolution glucose time-series data, clinical phenotype, and multiple molecular biomarkers.
Registry-Related Quality Procedures and Data Governance Although this study is not a patient registry in the classical sense, the research team implements registry-grade data management procedures due to the scale, multidimensionality, and long-term value of the dataset. The following subsections reflect the registry-quality framework.
- Quality Assurance Plan A comprehensive quality assurance (QA) plan governs all activities from recruitment to data analysis. Key components include: Standardized training of all personnel (dietitians, research nurses, data managers). Calibration schedules for anthropometric devices (stadiometer, scale, bioimpedance instruments) and for blood pressure monitors. Daily consistency checks of CGM data uploads. Protocol deviation logs documenting missing measurements, device issues, and participant non-compliance. Internal monthly audits performed by the IMDEA Quality Office to verify protocol adherence. Independent external audit capability is maintained, though audits are not routinely scheduled unless required by funders or ethics committees.
- Data Validation and Automated Data Checks Incoming data are processed through a multi-stage validation pipeline:
- Range and plausibility checks Automatic filtering flags values outside expected biological ranges (e.g., impossible BMI, extreme macronutrient percentages, duplicate CGM timestamps).
- Internal consistency checks Cross-field validation identifies inconsistencies, such as: caloric intake mismatching macronutrient totals, dietary patterns incompatible with photographed meals, anthropometric values inconsistent across visits.
- Technical consistency CGM streams are checked for: signal dropouts longer than 15 minutes, abrupt shifts indicating sensor displacement, unrealistic glucose kinetics (rise/decay rates). Problematic sections are annotated but not deleted, preserving data integrity for sensitivity analyses.
- Source Data Verification (SDV) To ensure data accuracy and representativeness: Dietary records are cross-validated against food photographs and questionnaire responses. Medical history and medication data are verified against documents participants bring to Visit 2 (e.g., lab reports ≤ 6 months old). Blood pressure and anthropometry undergo dual measurement with two assessors performing random checks on 10% of sessions. CGM data are compared with participant logs describing sensor issues, physical activity peaks, and atypical meals. All verification steps follow Good Clinical Practice (GCP) documentation practices.
- Data Dictionary and Variable Coding
The study uses an extensive data dictionary organized into modules:
Sociodemographic module
Definitions, coding schemes (e.g., ISCED for education), universe and skip patterns.
Clinical phenotype module
Standard coding for medical conditions using ICD-10 when applicable. Definitions of metabolic syndrome markers and derived variables.
Anthropometry and body composition
Measurement rules, rounding conventions, and device-specific calibrations.
CGM module
Time-series format, sampling interval, sensor metadata, derived features, preprocessing rules.
Dietary variables
Food items mapped to validated food composition databases for Spain. Nutrient coding includes standardized units and upper/lower expected ranges.
Molecular biomarkers
Units, assay platforms, storage conditions, and laboratory reference values.
The dictionary includes more than 500 entries and is version-controlled.
SOPs govern all operational and analytic tasks, including:
Recruitment and informed consent CGM application, monitoring, and removal Anthropometric and BIA measurement Blood/urine sample collection, processing, aliquoting, and storage Data entry and double-entry verification for paper forms Food image capture guidelines and data upload protocol Use of the AI food-recognition system and manual override procedures Documentation of adverse events related to CGM or blood collection Dataset freeze procedures and change control for analysis scripts Secure storage, encryption, and pseudonymization workflows
SOPs are reviewed periodically and updated as needed.
- Sample Size Assessment
Using synthetic data generated during algorithm development, investigators determined that approximately 392 complete datasets provide adequate clustering stability:
Maximization of the Silhouette score (~0.67 at n=392). Near-minimal Davies-Bouldin index at ~392-588 samples. Robust PCA component stability at ≥350 participants.
Accounting for a 20% potential data-loss rate, 471 participants are targeted for recruitment.
- Missing Data Plan Missingness may arise from incomplete dietary records, sensor failures, lost images, or participant withdrawal.
The plan includes:
Classification of missingness as MCAR, MAR, or MNAR. Short-gap interpolation for CGM data gaps ≤ 20 minutes using cubic spline or Kalman smoothing.
Exclusion of unusable segments (e.g., sensor warm-up periods). Multiple imputation (MI) for covariates such as weight or blood pressure if only one visit yields valid measures.
Complete-case sensitivity analyses to confirm robustness of imputed models.
Retention strategies minimize missing data, but high technical data density ensures analytic viability even with partial loss.
- Statistical Analysis Plan (SAP) The SAP covers both algorithm validation and hypothesis-generating analyses. 8.1 Preprocessing
CGM normalization to individual baselines. PCA for dimensionality reduction. Unsupervised clustering (k-means and hierarchical) with bootstrapping. Feature engineering for peak characteristics and chrononutrition variables.
8.2 Glucotype generation and validation
Internal validation with Silhouette, Calinski-Harabasz, and Davies-Bouldin metrics.
Stability assessment through subsampling and perturbation tests.
8.3 Association analyses
ANOVA/Kruskal-Wallis for between-glucotype comparisons. Logistic and linear regression adjusting for key confounders. MANOVA for overall cardiometabolic profiles.
8.4 Dietary modelling
Multiple Correspondence Analysis (MCA) for dietary pattern extraction. Regression models linking nutrient intake to glucotype. Machine learning models (Random Forest, SVM, XGBoost) to predict meal-level glucose responses.
8.5 Predictive simulations Agent-based modelling is used to simulate hypothetical diet changes and predict personalized glucose responses under various nutritional scenarios.
8.6 Software and reproducibility Analyses are performed in Python and R, with scripts managed through version control, containerization (Docker), and reproducibility logs.
Conclusion The FiS protocol integrates advanced CGM analytics, AI-driven phenotyping, and detailed dietary and biochemical profiling to map the diversity of glucose regulation in adults without diabetes. The study applies rigorous registry-level quality procedures, including automated data validation, structured data dictionaries, SOPs, and a comprehensive statistical analysis plan. The resulting dataset and validated algorithm will support future work in personalized nutrition, early risk detection, and tailored dietary interventions.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Food_iSense Analytics Cohort | – | Device: Continuous glucose monitoring using a wearable sensor (flash interstitial glucose monitor)This cohort includes adults aged 18-70 years without diagnosed diabetes who undergo continuous glucose monitoring (CGM) for 14 days using a FreeStyle Libre 3 sensor. Participants complete structured dietary records, provide meal photographs for AI-based food recognition, and answer validated nutrition and physical-activity questionnaires. Anthropometry, body composition, blood pressure, and recent clinical history are collected at study visits. At the end of monitoring, fasting blood and first-morning urine samples are obtained for biochemical and molecular analyses. No therapeutic intervention is administered; instead, the study characterizes natural glucose-response patterns ("glucotypes") under free-living conditions and evaluates how diet, lifestyle, and metabolic traits relate to glycemic dynamics to support future precision-nutrition strategies. |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- The study population consists of community-dwelling adults aged 18-70 years, recruited from the general population through public advertisements, university campus postings, pharmacies, and primary care centers. Participants represent a broad, non-clinical community sample without diagnosed diabetes or severe metabolic disease. Recruitment is open to individuals living independently and able to maintain their usual daily routines. The population reflects a heterogeneous mix of sociodemographic backgrounds to ensure variability in dietary habits, lifestyle patterns, and glucose-response profiles.
Key inclusion criteria (9 listed)
- Adults aged 18 to 70 years.
- Willing and able to undergo 14 days of continuous glucose monitoring (CGM) using a wearable sensor.
- Able to maintain stable dietary habits during the monitoring period.
- Able and willing to complete dietary records, including two structured 3-day food logs.
- Able and willing to photograph all meals during the 14-day monitoring period following instructions provided.
Key exclusion criteria (9 listed)
- Diagnosed diabetes mellitus or other serious metabolic disorders.
- History of severe gastrointestinal, cardiovascular, or other medical conditions that may interfere with stable diet or physical activity during the study.
- Pregnant or breastfeeding women.
- Inability or unwillingness to comply with continuous glucose monitoring (CGM) procedures for 14 days.
- Participants with skin conditions or allergies that prevent safe use of a CGM sensor.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Continuous glucose monitoring using a wearable sensor (flash interstitial glucose monitor)The intervention consists of applying and wearing a 14-day continuous glucose monitoring (CGM) device that captures interstitial glucose every minute under free-living conditions. This wearable flash sensor is used exclusively for passive data collection; it does not provide insulin delivery, therapeutic adjustments, or real-time clinical management. What distinguishes this intervention is its integration into a multimodal data-capture system: participants simultaneously complete structured dietary records, submit standardized meal photographs for AI-based food recognition, and undergo detailed phenotyping. The CGM data are then processed through the study's proprietary GLIA algorithm to derive individualized glucose-response patterns ("glucotypes"). This combination of high-frequency glucose monitoring, dietary image analytics, and machine-learning modeling differentiates the device's use from typical clinical or self-management applications in other studies. | Device | Food_iSense Analytics Cohort |
Primary outcome
Glucotype Classification Derived From Continuous Glucose Monitoring Data
Time frame: Assessed continuously over 14 days of CGM wear, with glucotype classification calculated after completion of the full 14-day glucose-monitoring period for each participant.
The primary outcome is the glucotype assigned to each participant based on analysis of the 14-day continuous glucose monitoring (CGM) trace. Glucotypes reflect individualized patterns of glucose dynamics, capturing peak shape, amplitude, recovery, variability, and chrononutrition-related fluctuations. The classification is generated using the GLIA machine-learning algorithm, which incorporates preprocessing (normalization, artifact detection), multivariate feature extraction (including peak morphology descriptors, temporal patterns, and variability metrics), and unsupervised clustering with stability assessment. The outcome quantifies each participant's predominant glucose-response phenotype under free-living conditions and serves as the foundation for assessing associations with dietary intake, metabolic traits, and predictive modeling of glycemic responses.
13 secondary outcomes
Body mass index
Time frame: Measured during Visit 2 and Visit 3 across the 14-day monitoring period.
Waist circunference
Time frame: Assessed during Visit 2 and Visit 3 within the 14-day monitoring period.
Body Fat Percentage
Time frame: Measured during Visit 2 and Visit 3 across the 14-day monitoring period.
Muscle mass
Time frame: Measured during Visit 2 and Visit 3 within the 14-day CGM period.
Visceral Fat Index
Time frame: Measured during Visit 2 and Visit 3 over the 14-day monitoring period.
Resting Metabolic Rate (RMR)
Time frame: Measured during Visit 2 and Visit 3 during the 14-day CGM period.
Blood Pressure (Systolic and Diastolic)
Time frame: Measured during Visit 2 and Visit 3 within the 14-day monitoring period.
Fasting Glucose
Time frame: Collected once during Visit 3 after completion of the 14-day monitoring period.
Hemoglobin A1c (HbA1c)
Time frame: Measured during Visit 3 following the 14-day CGM period.
Total Cholesterol
Time frame: Assessed during Visit 3 after completion of the 14-day monitoring period.
LDL Cholesterol
Time frame: Measured during Visit 3 following the 14-day CGM period.
HDL Cholesterol
Time frame: Measured during Visit 3 after the 14-day monitoring period.
Triglycerides
Time frame: Assessed during Visit 3 after completion of the 14-day monitoring period.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Nov 2026.
- Background: PubMed 35856435Klonoff DC, Nguyen KT, Xu NY, Gutierrez A, Espinoza JC, Vidmar AP. Use of Continuous Glucose Monitors by People Without Diabetes: An Idea Whose Time Has Come? J Diabetes Sci Technol. 2023 Nov;17(6):1686-1697. doi: 10.1177/19322968221110830. Epub 2022 Jul 20.
- Background: PubMed 39755436Hengist A, Ong JA, McNeel K, Guo J, Hall KD. Imprecision nutrition? Intraindividual variability of glucose responses to duplicate presented meals in adults without diabetes. Am J Clin Nutr. 2025 Jan;121(1):74-82. doi: 10.1016/j.ajcnut.2024.10.007. Epub 2024 Dec 2.
- Background: PubMed 38487483Mao Y, Tan KXQ, Seng A, Wong P, Toh SA, Cook AR. Stratification of Patients with Diabetes Using Continuous Glucose Monitoring Profiles and Machine Learning. Health Data Sci. 2022 Apr 27;2022:9892340. doi: 10.34133/2022/9892340. eCollection 2022.
- Background: PubMed 30040822Hall H, Perelman D, Breschi A, Limcaoco P, Kellogg R, McLaughlin T, Snyder M. Glucotypes reveal new patterns of glucose dysregulation. PLoS Biol. 2018 Jul 24;16(7):e2005143. doi: 10.1371/journal.pbio.2005143. eCollection 2018 Jul.
- Background: PubMed 26590418Zeevi D, Korem T, Zmora N, Israeli D, Rothschild D, Weinberger A, Ben-Yacov O, Lador D, Avnit-Sagi T, Lotan-Pompan M, Suez J, Mahdi JA, Matot E, Malka G, Kosower N, Rein M, Zilberman-Schapira G, Dohnalova L, Pevsner-Fischer M, Bikovsky R, Halpern Z, Elinav E, Segal E. Personalized Nutrition by Prediction of Glycemic Responses. Cell. 2015 Nov 19;163(5):1079-1094. doi: 10.1016/j.cell.2015.11.001.
- Background: PubMed 34166426van Doorn WPTM, Foreman YD, Schaper NC, Savelberg HHCM, Koster A, van der Kallen CJH, Wesselius A, Schram MT, Henry RMA, Dagnelie PC, de Galan BE, Bekers O, Stehouwer CDA, Meex SJR, Brouwers MCGJ. Machine learning-based glucose prediction with use of continuous glucose and physical activity monitoring data: The Maastricht Study. PLoS One. 2021 Jun 24;16(6):e0253125. doi: 10.1371/journal.pone.0253125. eCollection 2021.
- Background: PubMed 40817355Barrea L, Verde L, Colao A, Mandarino LJ, Muscogiuri G. Medical nutrition therapy for the management of type 2 diabetes mellitus. Nat Rev Endocrinol. 2025 Dec;21(12):769-782. doi: 10.1038/s41574-025-01161-5. Epub 2025 Aug 15.
- Background: PubMed 35282442Safiri S, Karamzad N, Kaufman JS, Bell AW, Nejadghaderi SA, Sullman MJM, Moradi-Lakeh M, Collins G, Kolahi AA. Prevalence, Deaths and Disability-Adjusted-Life-Years (DALYs) Due to Type 2 Diabetes and Its Attributable Risk Factors in 204 Countries and Territories, 1990-2019: Results From the Global Burden of Disease Study 2019. Front Endocrinol (Lausanne). 2022 Feb 25;13:838027. doi: 10.3389/fendo.2022.838027. eCollection 2022.
- Individual participant dataSharing planned: Yes. De-identified individual participant data will be made available to qualified researchers upon reasonable request. All shared datasets will undergo double codification, meaning two independent pseudonymization layers are applied before external release: one ID replacing personal identifiers within IMDEA Nutrition, and a second external-use ID generated solely for data sharing. No key linking either code to participant identities will be shared. Data will be accessible only for ethically approved scientific purposes and after signing a data-sharing agreement outlining permitted use, data-security requirements, and obligations to prevent re-identification. Access will be provided through secure, controlled-transfer procedures.
Related trials for Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)
Enrolling by invitationEarly Phase 1
Truway Diagnostic Tools in Primary Care
Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Active, not recruiting
The Effect of Exercise and Nicotinamide Riboside Muscle Health and Insulin Resistance in Survivors of Childhood Cancer
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Not yet recruitingPhase 4
Effect of SGLT2 Inhibitor on Metabolic-Dysfunction-Associated Fatty Liver Disease in Patients With Insulin Resistance
MAFLD in Prediabetes and Diabetes
RecruitingObservational study
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Type 2 Diabetes, Insulin Resistance
RecruitingPhase 2
Effects of Different Fish Oil Types on Type 2 Diabetes Risk Factors in High-Risk Adults
Type 2 Diabetes, Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Prediabetes (Insulin Resistance, Impaired Glucose Tolerance) and Artificial Intelligence Mobile Application, run by IMDEA Food at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 5 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Lidia Daimiel Ruiz, Senior Researcher (+34655250563, lidia.daimiel@nutricion.imdea.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Glucotype Classification Derived From Continuous Glucose Monitoring Data (time frame: Assessed continuously over 14 days of CGM wear, with glucotype classification calculated after completion of the full 14-day glucose-monitoring period for each participant.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07626658, which also lists 8 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Nov 2026.